share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

辉瑞 | 4：持股变动声明-董事 NARAYEN SHANTANU
美股sec公告 ·  04/26 13:28
Moomoo AI 已提取核心信息
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
辉瑞公司 [PFE] 的举报人尚塔努·纳拉延于2024年4月25日参与了一笔交易。公告中未披露交易的具体细节，包括行动类型、状态、所涉股份数量、股票性质、交易价格和交易后的持股情况。因此，该事件对纳拉延持股和辉瑞整体市场地位的影响尚不清楚。
辉瑞公司 [PFE] 的举报人尚塔努·纳拉延于2024年4月25日参与了一笔交易。公告中未披露交易的具体细节，包括行动类型、状态、所涉股份数量、股票性质、交易价格和交易后的持股情况。因此，该事件对纳拉延持股和辉瑞整体市场地位的影响尚不清楚。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息